Agile 3+ Index Is Independently Associated With Cardiovascular Diseases in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease: Analysis of NHANES 2017–2020
Diabetes/Metabolism Research and Reviews · 2026
DOI: 10.1002/dmrr.70123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2026. Verfasst von Yan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Biomarkers, Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit nennt 36 Literaturangaben. Gefördert von: China International Medical Foundation, Noncommunicable Chronic Diseases-National Science and Technology Major Project, 2024 Shanghai Oriental Talents - Technology Platform Program.
Abstract (Originalsprache)
Background
The Agile 3+ score, recently developed based on transient elastography measurements, transaminase ratios, and metabolic parameters, effectively assesses fibrosis in metabolic dysfunction‐associated steatotic liver disease (MASLD). This study aimed to evaluate the association between Agile 3+ and cardiovascular diseases (CVD) in MASLD and to compare its predictive performance with Agile 4, Fibrosis‐4 (FIB‐4), and FibroScan aspartate aminotransferase (FAST).
Methods
We analysed data in 3198 patients with MASLD during the 2017–March 2020 prepandemic from National Health and Nutrition Examination Survey. The associations between Agile 3+ and CVD were assessed using univariate and multivariable logistic regression models. Predictive accuracy was evaluated via receiver operating characteristic curves and decision curve analysis (DCA).
Results
Among 3198 patients with MASLD, 385 (12.0%) had CVD. After adjusting for confounders, a dose‐dependent relationship was observed between Agile 3+ and CVD risk: compared to the reference group, the odds of CVD increased by 58% in the 0.45–0.68 group (OR 1.58, 95%CI 1.13–2.20, p = 0.008) and by 78% in the ≥ 0.68 group (OR 1.78, 95%CI 1.22–2.59, p = 0.003). In the context of CVD risk prediction, Agile 3+ and FIB‐4 achieved the highest AUC (0.71), outperforming Agile 4 (0.64) and FAST (0.51). DCA revealed that Agile 3+ provided superior net benefit within the 20%–40% CVD risk threshold range. Furthermore, subgroup and sensitivity analyses further confirmed the robustness of the results.
Conclusions
Agile 3+ is independently associated with CVD in patients with MASLD and demonstrates better predictive performance than Agile 4, FIB‐4, and FAST scores.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Förderung
- China International Medical Foundation
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- 2024 Shanghai Oriental Talents - Technology Platform Program
- National Major Science and Technology Projects of China
Zitieren
APA
Li, Y., Yang, M., Yue, J., Wang, Z., Qi, Y., Liu, Q., & Ma, J. (2026). Agile 3+ Index Is Independently Associated With Cardiovascular Diseases in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease: Analysis of NHANES 2017–2020. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70123
Vancouver
Li Y, Yang M, Yue J, Wang Z, Qi Y, Liu Q, et al. Agile 3+ Index Is Independently Associated With Cardiovascular Diseases in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease: Analysis of NHANES 2017–2020. Diabetes/Metabolism Research and Reviews. 2026. doi:10.1002/dmrr.70123
BibTeX
@article{Li2026,
author = {Li, Yan and Yang, Minglan and Yue, Jiang and Wang, Zixuan and Qi, Yicheng and Liu, Qianjing and Ma, Jing},
title = {Agile 3+ Index Is Independently Associated With Cardiovascular Diseases in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease: Analysis of NHANES 2017–2020},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
doi = {10.1002/dmrr.70123}
}
EUVIMED